terlipressin   Click here for help

GtoPdb Ligand ID: 11241

Synonyms: glycyl-glycyl-glycyl-L-cysteinyl-L-tyrosyl-L-phenylalanyl-L-glutaminyl-L-asparagyl-L-cysteinyl-L-prolyl-L-lysyl-glycinamide (4->9)-disulfide | Glypressin® | N-(N-(N-Glycylglycyl)glycyl)-8-L-lysinevasopressin | Terlivaz® | Variquel®
Approved drug
terlipressin is an approved drug (UK (2001), FDA (2022))
Compound class: Peptide or derivative
Comment: Terlipressin is a clinically used vasopressin analogue. Terlipressin is biotransformed to its active moiety, lysine vasopressin (LVP). It has vasoconstrictive, antihemorrhagic, and antidiuretic properties.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES NCCCC[C@@H](C(=O)NCC(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](Cc2ccc(cc2)O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC(=O)N)CCC(=O)N)Cc1ccccc1
Isomeric SMILES NCCCC[C@@H](C(=O)NCC(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](Cc2ccc(cc2)O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC(=O)N)CCC(=O)N)Cc1ccccc1
InChI InChI=1S/C52H74N16O15S2/c53-17-5-4-9-31(45(76)60-23-41(57)72)63-51(82)38-10-6-18-68(38)52(83)37-27-85-84-26-36(61-44(75)25-59-43(74)24-58-42(73)22-54)50(81)65-34(20-29-11-13-30(69)14-12-29)48(79)64-33(19-28-7-2-1-3-8-28)47(78)62-32(15-16-39(55)70)46(77)66-35(21-40(56)71)49(80)67-37/h1-3,7-8,11-14,31-38,69H,4-6,9-10,15-27,53-54H2,(H2,55,70)(H2,56,71)(H2,57,72)(H,58,73)(H,59,74)(H,60,76)(H,61,75)(H,62,78)(H,63,82)(H,64,79)(H,65,81)(H,66,77)(H,67,80)/t31-,32-,33-,34-,35-,36-,37-,38-/m0/s1
InChI Key BENFXAYNYRLAIU-QSVFAHTRSA-N
No information available.
Summary of Clinical Use Click here for help
Terlipressin is used as a vasoactive drug in the management of low blood pressure, principally when norepinephrine is ineffective. It also helps prevent urination. Indications for use include norepinephrine-resistant septic shock and hepatorenal syndrome. Terlipressin is approved for use in a number of countries, but not under EMA authorisation. Terlipressin was evaluated for efficacy in patients with hepatorenal syndrome type 1 (HRS-1) [1-2]. FDA approval for terlipressin (Terlivaz), as a treatment to improve kidney function in patients with hepatorenal syndrome, was granted in September 2022.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01143246 A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin Phase 3 Interventional Mallinckrodt Despite demonstrating an improvement in overall survival in patients with HRS-1, the FDA declined to approve terlipressin (in 2020) for this indication, stating that they would require more information to support a positive risk-benefit profile before reconsidering their decision. 2
External links Click here for help
For extended ADME data see the following:

Electronic Medicines Compendium (eMC)